Emcure Pharmaceuticals’ shares had an excellent Dalal Street debut on Wednesday when they were listed on the NSE at Rs 1,325.05, which is 31.45% more than the stock’s issue price of Rs 1,008. Similarly, the stock was also listed on the BSE at the same price and premium.
However, the actual listing has followed the predicted lines for investors. Emcure Pharma’s shares were trading at a grey market premium (GMP) of Rs 300 per share prior to the IPO, implying a 30% increase in value for investors.
Emcure Pharma’s IPO was open for bidding between July 3 and July 5. The Pune-based pharma firm issued its shares at a price range of Rs 960-1,008 per share with a lot size of 14 shares. With its primary offering, which included an offer-for-sale (OFS) of up to 79,36,507 shares and a new share sale of Rs 800 crore, the firm raised Rs 1,952.03 crore.
Established in 1981, Emcure Pharma is a homegrown pharmaceutical company that creates, produces and distributes a wide range of pharmaceutical products worldwide, covering several significant therapeutic areas. The firm operates thirteen manufacturing facilities across India.
Disclaimer: The information provided in this article is for informational purposes only and should not be considered as financial advice. The data and figures presented are based on publicly available information and may be subject to change. Before making any investment decisions, it is recommended to conduct thorough research, consult with financial advisors, and consider your individual investment goals and risk tolerance. The author and publisher of this article do not assume any responsibility for any investment decisions made based on the information provided.